This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Pharmacyclics Has Edge Over Blood Cancer Competitors

Stocks in this article: PCYC GILD ABBV

NEW YORK (TheStreet) -- Pharmacyclics (PCYC) has been an interesting bull/bear stock this year as investors debate the long term potential of Imbruvica in B-cell malignancies. Imbruvica is clearly a marked improvement from the standard of care but the question is how will it wrestle market share from well-established treatments and fend off competition from fast followers such as Gilead Sciences' (GILD) Zydelig and Abbvie's (ABBV) ABT-199.

Imbruvica sales to date have exceeded Wall Street consensus expectations, but the drug is competing against older and less effective therapies.

The recent FDA approval of Gilead's Zydelig was actually a positive for Pharmacyclics and Imbruvica. The Zydelig label contains a black box safety warning that is worse than expectations for severe diarrhea, pneumonitis and intestinal perforation. In contrast, Imbruvica's label is clean from a safety perspective and was recently expanded to include additional indications. Judging the labels side by side, Zydelig should have a tougher time competing against Imbruvica than previously expected.

Helping Pharmacyclics further: Imbruvica has a total cost advantage over Zydelig because it must be combined with Roche's Rituxan. Imbruvica is used on its own.

Looking a couple of years down the road, Imbruvica faces potentially formidable competition from Abbvie's ABT-199, which appears more potent but also carries added toxicity concerns. It is not clear at this point how the market will shake out between the two drugs (do you put a preference on efficacy with additional toxicity or prefer a clearly active agent that is more tolerable?) so this will continue to be a hot topic of debate and contention.

Of course, even if Imbruvica is able to keep an edge on ABT-199, coming next will be competition from a slew of CAR-T therapies, which might further raise the efficacy bar with perhaps even more acute toxicity issues than ABT-199. At this point, it is impossible to know exactly how the future treatment paradigms will develop but given its current usage and the toxicities highlighted in the Zydelig label, Imbruvica will be an important part of the treatment landscape for blood cancers.

Sobek is long Gilead, Abbvie, and Pharmacyclics.

David Sobek has been writing on biotech for a number of years through various outlets with a general focus on small cap oncology and antibiotics companies. He received his PhD in political science from Pennsylvania State University in 2003 and a BA in international relations from The College of William and Mary in 1997.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs